India is often called the diabetes capital of the world. From your perspective, what are the biggest challenges in diabetes ...

Abbott Launches Next-Gen FreeStyle Libre® 2 Plus with Continuous Glucose Readings Every Minute & Optional Alarms ...

Although Abbott Laboratories has underperformed its industry peers recently, analysts remain highly optimistic about the ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Mobile, and Abbott lead Zacks Research Daily with AI gains, 5G leadership, and strong medical device pipelines driving ...

These healthcare leaders are well-established dividend payers -- all three are in the exclusive group of Dividend Kings that ...

The global Digital Health Market, valued at US$162.1 billion in 2024, stood at US$199.1 billion in 2025 and is projected to ...

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Pfizer (NYSE: PFE).

Medtronic has obtained a pair of major green lights from the FDA for its flagship insulin pump—opening up the MiniMed 780G to adults with type 2 diabetes in the U.S., and allowing it to c | ...

If you opt to reinvest the dividend -- currently yielding 1.8% -- you'll see returns boosted over the ... Abbott has also had to recall some FreeStyle Libre sensors due to possibly inaccurate glucose ...

Hybrid closed-loop systems were associated with improved glycemic control and safety during prolonged daytime fasting in type 1 diabetes.

Dutch device company ViCentra has raised $85m to boost its Kaleido insulin patch pump’s entry onto the US market.